BSD medical: Clinical study using hyperthermia combined with chemotherapy to treat children and adolescents shows promise

Abstract

BSD Medical Corp. reported on clinical data presented by Rudiger

Wessalowski, M.D, Associate Professor at the Clinic of Pediatric

Hematology and Oncology, Heinrich-Heine University, Dusseldorf,

Germany, on the use of hyperthermia combined with chemotherapy and

tumor resection to treat malignant germ cell tumors in children and

adolescents. Dr. Wessalowski presented an update of his clinical study

at the annual Society for Thermal Medicine (STM) meeting that was held

in Tucson, Arizona on April 4 to April 7, 2009.

Dr. Wessalowski reported on the use of the BSD-2000 to treat 101

pediatric patients who ranged from age 7 months to 17 years old with a

median age of five years. Of these 101 patients, 46 patients had

malignant germ cell tumors. Of the 46 patients with germ cell tumors,

there were 23 patients who had a complete response (disappearance of

all local disease) and 8 patients with a partial response (greater than

50% reduction). The median follow-up was 5 years. The best responders

were patients who received the combined treatment as first time

therapy.

Dr. Wessalowski noted that standard therapies are often not effective

for certain children's cancers, and relapse therapy is often not

effective or available. The study was designed to not only improve

survival but also avoid mutilating surgery. Dr. Wessalowski reported

that the results of the current study found that combined hyperthermia

and platinum-based chemotherapy can be used in children and

adolescents. This regimen was found to result in objective tumor

response (complete plus partial response) in approximately 67% of study

patients who had germ cell tumors. According to Dr. Wessalowski,

preoperative platinum-based chemotherapy combined with regional

hyperthermia facilitates complete tumor resection in some patients.

Dr. Wessalowski also presented magnetic resonance images showing the

temperature changes in children using the BSD-2000/3D/MR to deliver the

hyperthermia and simultaneously measure the temperature changes. The

Heinrich-Heine University, Dusseldorf, Germany had recently added a new

BSD-2000/3D/MR system to further enhance the treatment capacity of its

hyperthermia therapy program. The new system integrates a BSD-2000/3D

Deep Regional Hyperthermia System with a Siemens 1.5 Magnetic Resonance

Imaging (MRI) system. To accommodate the treatment of children, the

system uses a set of reduced-size, special pediatric applicators.

About Heinrich-Heine University, Dusseldorf, Germany

The University Pediatric Oncology Clinic at Dusseldorf has taken the

lead on several national and international studies designed to optimize

pediatric oncology therapy. For more than 10 years the Dusseldorf

Pediatric Oncology Department has pioneered the application of

hyperthermia therapy for treating children's cancers using a BSD-2000

for the treatment of soft tissue sarcomas and germ cell tumors.

About BSD Medical Corporation

BSD Medical is a leading developer of systems used to provide cancer

therapies requiring precision-focused heat through RF/microwave

technologies. The company's systems have been designed to kill cancer

through heat alone, and as companion therapies to improve the combined

results when used along with radiation treatments. The BSD-2000 is

limited to investigational use in the United States. For further

information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical

facts are forward-looking statements, as defined in the Private

Securities Litigation Reform Act of 1995. All forward-looking

statements are subject to risks and uncertainties detailed in the

Company's filings with the Securities and Exchange Commission. These

forward-looking statements speak only as of the date on which such

statements are made, and the Company undertakes no obligation to update

such statements to reflect events or circumstances arising after such

date.

CONTACT:

Harold R. Wolcott

[phone]